How will Australia's traditional approach to health technology assessment manage a multi-million dollar one-time injection with the 'potential' to cure and add 40, 50, 60 or even 70 years of normal life expectancy? The US could lead the way.
Do you value a lifetime benefit based on almost no evidence?
May 29, 2019 Latest NewsNews of the Day
Latest Video
New Stories
-
Algorae signs two-part deal with Umedica to expand Australian portfolio
October 19, 2026 - - Latest News -
Novartis, Boehringer Ingelheim leaders join Medicines Australia board
October 19, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5. Ep.36
October 19, 2026 - - Podcast -
Cancer physicians now running communication skills workshops on how to discuss private pay
October 19, 2026 - - Latest News -
'If your doctor prescribes it, it should be covered,' pollster recommends as the key message
October 19, 2026 - - Latest News -
Global headwinds and new contenders set the agenda for Australia's 'Biggest Week in Biotech'
October 19, 2026 - - Latest News -
Mixed PBAC outcomes for multi-cancer immunotherapy listings
October 19, 2026 -
